s2365
NM_001221.3
NM_001321566.1
NM_001321567.1
NM_001321568.1
NM_001321569.1
NM_001321570.1
NM_001321571.1
NM_001321572.1
NM_001321573.1
NM_001321574.1
NM_001321575.1
NM_001321576.1
NM_001321577.1
NM_001321578.1
NM_001321579.1
NM_001321580.1
NM_001321581.1
NM_001321582.1
NM_001321583.1
NM_001321584.1
NM_001321585.1
NM_001321586.1
NM_001321587.1
NM_001321588.1
NM_001321589.1
NM_001321590.1
NM_001321591.1
NM_172114.1
NM_172115.2
NM_172127.2
NM_172128.2
NM_172129.1
XM_005263253.3
XM_005263254.3
XM_006714330.2
XM_011532289.1
XM_011532290.1
XM_011532291.1
XM_011532295.1
XM_017008672.1
XM_017008673.1
XM_017008674.1
XM_017008675.1
XM_017008676.1
XM_017008677.1
XM_017008678.1
13%(+/-3% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00241833_m1]
HeLa cells were reverse transfected with 5 nM gene-specific Silencer® Select siRNA or 5 nM Silencer® Select Negative Control #2 siRNA, using siPORT™ NeoFX™ Transfection Agent. 48 hours post-transfection, RNA was isolated, and then two-step, quantitative RT-PCR was performed using an appropriate TaqMan® Gene Expression Assay. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.